Cytori reports publication of interim pilot data for Cellcordes trial
Cytori Therapeutics announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of "Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report." This report describes preliminary data from the CELLCORDES trial of Cytori Cell Therapy in patients with severe voice dysfunction due to scarring of the vocal fold. The CELLCORDES trial is a fully-enrolled investigator-initiated pilot trial conducted using Cytori Cell Therapy. The trial is being performed by Investigators at the Department of Oto-Rhino-Laryngology and Head and Neck Surgery of Aix-Marseille University and the Cell Therapy Laboratory of La Conception University Hospital, both of Marseille, France. The reported index patient had severe vocal dysfunction persisting for four years following traditional surgery to treat chronic vocal fold lesions. Twelve months after single direct administration with 12 million ADRCs, the patient exhibited improvements in Vocal Handicap Index and other qualitative and quantitative measures of voice quality including: Hirano's GRB scale, Jitter, and vocal range. The authors noted that while the remaining seven patients treated in the CELLCORDES study have yet to complete 12-months of follow-up, no serious adverse events have been reported in any subject and no subject has reported worsening of vocal function. Furthermore, three are exhibiting "very good results (especially on the VHI)".